Current Headlines

  1. Infection-Fighting Biosimilars Expected To Hit $1.8B By 2023
    11/25/2014

    Decisions Resources Group (DRG) surveyed oncologists from France and Germany to gauge their opinion and preferences toward a wave of biosimilars which are poised to enter the market over the next few years.

  2. Amgen Opens Biologics Manufacturing Facility In Singapore
    11/25/2014

    Amgen has finished construction of its biologics manufacturing facility in Tuas, Singapore.

  3. First Chikungunya Vaccine Succeeds In Phase 1 Study
    11/25/2014

    Vienna-based biotech company, Themis Bioscience, has announced the positive results from a phase 1 clinical study of its prophylactic Chikungunya fever vaccine candidate.

  4. ChemoCentryx Gets FDA Orphan Status For Kidney Disease Drug
    11/25/2014

    Clinical stage biopharmaceutical company ChemoCentryx announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CCX168 as an investigational treatment for atypical Hemolytic Uremic Syndrome (aHUS).

  5. Bristol-Myers Squibb, Five Prime Partner On Opdivo, FPA008 In Tumors
    11/25/2014

    Bristol-Myers Squibb Company (BMS) and Five Prime Therapeutics have entered into a partnership to investigate a combination of BMS’ Opdivo (nivolumab) and Five Prime’s FPA008 to treat six types of malignant tumors.

  6. FDA Grants Orphan Drug Status To Bio Blast’s Cabaletta For Spinocerebellar Ataxia Type 3
    11/24/2014

    Bio Blast Pharma announced in a press release that the Food and Drug Administration (FDA) has granted Orphan Drug status to Cabaletta in the treatment of Spinocerebellar Ataxia type 3, the second Orphan designation for Cabaletta.

  7. FDA Fast Tracks Merrimack’s, Baxter’s MM-398 For Pancreatic Cancer
    11/24/2014

    Merrimack Pharmaceuticals announced in a press release that the Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal irinotecan injection) Fast Track designation.

  8. Basilea's BAL101553, Radiotherapy Delays Tumor Growth
    11/24/2014

    Compared to BAL101553 monotherapy, Basilea’s investigational agent combined with radiotherapy significantly delays tumor growth.

  9. Celldex’s Brain Cancer Vaccine Shows Promising Interim Results
    11/24/2014

    New Jersey-based biotech company Celldex Therapeutics has reported the positive interim results from a Phase 2 study of its novel brain cancer immunotherapy vaccine, rindopepimut, in patients with recurrent glioblastoma.

  10. BerGenBio’s AML Drug Granted FDA Orphan Status
    11/24/2014

    Oncology biopharmaceutical company BerGenBio announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug BGB324 as treatment for acute myeloid leukemia (AML).

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.